Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, has received a cash refund of A$705,193 through the Australian Government's Research and Development Tax Incentive for the fiscal year ending June 2022. The refund stems from Lumos' research and development efforts to enhance its proprietary reader technology platform, which aids in interpreting results from POC diagnostic tests and seamlessly integrating them with electronic medical record systems.
This platform has played a crucial role in recent contract wins with Hologic and the Burnet Diagnostics Initiative of the MacFarlane Burnet Institute. Lumos CEO Doug Ward expressed gratitude for the government's support, highlighting how the funding has advanced research on the reader technology platform and the development of novel POC tests to enhance human health outcomes. Lumos Diagnostics specializes in affordable, rapid POC diagnostic tests and offers customized assay development and manufacturing services for POC tests, along with proprietary digital reader platforms.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
